The US Food and Drug Administration (FDA) has granted 510(k) clearance to Monteris Medical's NeuroBlate system for the treatment of brain tumors and other lesions.
The MRI system embedded in the device provides visualization and allows neurosurgeons to ablate (lethally heat) diseased brain tissue with the use of a surgical laser and a software platform.
The neurosurgical ablation device also supports surgical decision making during brain operations and provides post-procedure confirmation of the effects of the thermal therapy.
Cleveland Clinic Neurological and Cancer Institutes neurosurgical oncology chair Gene Barnett said the device makes laser ablation of brain lesions accessible to more neurosurgeons with the intuitive user interface and time-saving enhancements.
"Cleveland Clinic will soon be employing this tool to treat brain tumor patients who are seeking a minimally invasive option or are not candidates for traditional surgery," Barnett added.
Monteris Medical president and CEO John Schellhorn said the company invested significant resources to develop a laser ablation system that is faster and adapts to contemporary clinical workflow.
"We believe the NeuroBlate System will offer a new option for surgeons managing patients with brain tumors and other neurologic lesions," Schellhorn added.
